Some are approved for type 2 diabetes or chronic weight management
While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, transient, mild-to-moderate bouts of the following issues are commonplace among GLP-1 drugs: Nausea : 44% Vomiting: 25% Diarrhea: 32% Constipation: 23% Abdominal pain: 10% Fatigue, Dizziness, Headache Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue
However, you may not be a candidate for certain medications if you have or have had thyroid cancer, have a strong family history of MEN (multiple endocine neoplasia), gastropareisis, or Type 1 diabetes
Proponents of combining NAD+ supplementation with tirzepatide suggest several theoretical benefits, though it is crucial to emphasize that these potential synergies are largely speculative and not supported by clinical trial evidence
Recovery from both physical and mental stress becomes notably faster